Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QTSWGPEM: sourced facts only. name: "QTSWGPEM and QPSGGPYM were obtained and proven to be capable of binding to p53 protein in the enzyme-linked immunosorbent assay (ELISA) and the fluorescence polarization (FP) assay." [PMID:42398393]; target: "QTSWGPEM and QPSGGPYM were obtained and proven to be capable of binding to p53 protein in the enzyme-linked immunosorbent assay (ELISA) and the fluorescence polarization (FP) assay." [PMID:42398393]; developer: "Department of Biochemical Engineering, School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Frontier Science Center for Synthetic Biology, Key Laboratory of Systems Bioengineering (MOE), Tianjin University, Tianjin 300350, China." [PMID:42398393]; modality: "Herein, peptide inhibitors were designed to inhibit the interaction between p53 protein and ubiquitin ligase COP1." [PMID:42398393]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QTSWGPEM.